- Home
- EML vs ALEC Comparison
EML vs ALEC Comparison
Compare EML & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EML | ALEC |
|---|---|---|
| Founded | 1858 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.2M | 193.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | EML | ALEC |
|---|---|---|
| Price | $18.30 | $1.85 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 17.4K | ★ 1.3M |
| Earning Date | 11-04-2025 | 02-25-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $258,121,226.00 | $69,048,000.00 |
| Revenue This Year | $1.56 | N/A |
| Revenue Next Year | $7.00 | $155.87 |
| P/E Ratio | $17.62 | ★ N/A |
| Revenue Growth | N/A | ★ 12.26 |
| 52 Week Low | $18.11 | $0.87 |
| 52 Week High | $29.55 | $3.40 |
Technical Indicators
Market Signals| Indicator | EML | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 38.72 | 72.49 |
| Support Level | $18.11 | $1.50 |
| Resistance Level | $19.06 | $1.62 |
| Average True Range (ATR) | 0.78 | 0.09 |
| MACD | -0.15 | 0.05 |
| Stochastic Oscillator | 3.81 | 94.23 |
Price Performance
Historical ComparisonAbout EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.